<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03113955</url>
  </required_header>
  <id_info>
    <org_study_id>S2382</org_study_id>
    <nct_id>NCT03113955</nct_id>
  </id_info>
  <brief_title>STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma</brief_title>
  <official_title>A Single-arm Trial of Transcatheter Arterial Chemoembolization With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Varian Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Varian Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in&#xD;
      the Treatment of Localized Hepatocellular Carcinoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a prospective, single-arm, multicenter study. The primary effectiveness endpoint for&#xD;
      this clinical trial is 6-month overall objective tumor response (ORR).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2017</start_date>
  <completion_date type="Actual">February 28, 2020</completion_date>
  <primary_completion_date type="Actual">June 28, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Objective Tumor Response at 6 Months by MRI (Magnetic Resonance Imaging)</measure>
    <time_frame>At 6 months</time_frame>
    <description>The objective response rate measured by MRI used EASL (European Society for the Study of the Liver) and mRECIST (Improved criteria for evaluating the efficacy of solid tumors) , Overall Response (OR) = CR + PR.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (mRECIST ) for target lesions : Complete Response (CR), Disappearance of any intratumoral arterial enhancement in all target lesions; Partial Response (PR), At least a 30% decrease in the sum of the diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (EASL) for target lesions: Complete Response (CR), Disappearance of all known disease and no new lesions determined by two observations not less than 4 weeks apart; Partial Response (PR), At least 50% reduction in total tumor load of all measurable lesions determined by two observations not less than 4 weeks apart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Analyses the Percent of Participants for Time to Progression (TTP) at 12 Months</measure>
    <time_frame>At 12 months</time_frame>
    <description>Kaplan-Meier analyses the percent of participants for TTP which is defined as the length of time from the treatment initiation to either the date of the first disease progression occurred, as assessed by the investigators, or the date of the subject died due to any cause, whichever comes earlier. EASL and mRECIST response assessment of target lesion for HCC. TTP (also referred as &quot;time to treatment failure&quot;) will be measured by a few data items list below:&#xD;
The date of the disease progression in the Overall Response form&#xD;
The date of lost-to-follow due to:&#xD;
Adverse events&#xD;
Progressive disease/insufficient therapeutic response&#xD;
Death&#xD;
Failure to return&#xD;
Refusing treatment/being unwilling to cooperate/withdrawing consent&#xD;
The very last date by scanning all available dates in the database&#xD;
The desired cut-off days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Objective Tumor Response at 30-day</measure>
    <time_frame>At 1month</time_frame>
    <description>The objective response rate measured by MRI used EASL (European Society for the Study of the Liver) and mRECIST (Improved criteria for evaluating the efficacy of solid tumors) , Overall Response (OR) = CR + PR.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (mRECIST ) for target lesions : Complete Response (CR), Disappearance of any intratumoral arterial enhancement in all target lesions; Partial Response (PR), At least a 30% decrease in the sum of the diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (EASL) for target lesions: Complete Response (CR), Disappearance of all known disease and no new lesions determined by two observations not less than 4 weeks apart; Partial Response (PR), At least 50% reduction in total tumor load of all measurable lesions determined by two observations not less than 4 weeks apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Analyses the Percent of Participants for PPF(Proportion Progression-Free) at 12 Months</measure>
    <time_frame>from first TACE to 12 months</time_frame>
    <description>Kaplan-Meier analyses the percent of participants for PPF which is defined as the length of time from the treatment initiation, that treated subjects are still progression-free. EASL and mRECIST response assessment of target lesion for HCC.&#xD;
The data items to be captured will include:&#xD;
The date of the disease progression in the Overall Response form&#xD;
The very last date by scanning all available dates in the database&#xD;
The desired cut-off days The proportion of any time point will be determined by the Kaplan-Meier estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Analyses the Percent of Participants for Overall Survival</measure>
    <time_frame>from first TACE to 12 months</time_frame>
    <description>Kaplan-Meier analyses the percent of participants for Overall survival which is defined as the length of time from the treatment initiation, that treated subjects are still alive. The Kaplan-Meier analysis is aimed to capture the all-cause death for each subject. Subjects who are lost-to-follow will be considered being censored.&#xD;
There are three critical data items to be captured:&#xD;
Death date&#xD;
The very last date in the database (e.g. follow-up visit date and/or site reported AE date)&#xD;
The desired cut-off days (e.g. 6-month OS at 182 days, 12-month OS at 365 days) In addition to the Kaplan-Meier survival curve, the median survival time (mOS) will also be used to represent the study cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events Relate to Study Device in 12 Months Post Procedure</measure>
    <time_frame>in 12 months</time_frame>
    <description>Number and documents of adverse events relate to study device in 12 months post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Objective Tumor Response at 3 Months</measure>
    <time_frame>At 3 months</time_frame>
    <description>The objective response rate measured by MRI used EASL (European Society for the Study of the Liver) and mRECIST (Improved criteria for evaluating the efficacy of solid tumors) , Overall Response (OR) = CR + PR.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (mRECIST ) for target lesions : Complete Response (CR), Disappearance of any intratumoral arterial enhancement in all target lesions; Partial Response (PR), At least a 30% decrease in the sum of the diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (EASL) for target lesions: Complete Response (CR), Disappearance of all known disease and no new lesions determined by two observations not less than 4 weeks apart; Partial Response (PR), At least 50% reduction in total tumor load of all measurable lesions determined by two observations not less than 4 weeks apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Analyses the Percent of Participants for Time to Extrahepatic Spread</measure>
    <time_frame>At 12 month</time_frame>
    <description>Kaplan-Meier analyses the percent of participants for Time to Extrahepatic Spread which the length of time from the treatment initiation to the development of extrahepatic spread of the disease via imaging assessment.&#xD;
The data items to be considered will include:&#xD;
The date of the extrahepatic spread in the Overall Response form&#xD;
The very last date by scanning all available dates in the database&#xD;
The desired cut-off days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Localized Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>single -arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tandem Microsphere loaded with Epirubicin</intervention_name>
    <description>The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)</description>
    <arm_group_label>single -arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is able to provide informed consent and must sign the Institutional Review&#xD;
             Board/Ethics Committee (IRB/EC) approved Informed Consent Form.&#xD;
&#xD;
          2. Male or female of age ≥18 and ≤75 years.&#xD;
&#xD;
          3. Confirmed diagnosis of HCC according to the diagnostic criteria included in the&#xD;
             management guideline issued by China's Ministry of Health in 2017.&#xD;
&#xD;
          4. HCC is diagnosed for the first time or recurrence of tumor after surgical or ablation&#xD;
             treatment.&#xD;
&#xD;
          5. Single tumor less than 7cm in diameter or multiple tumors with maximum 3 lesions with&#xD;
             &gt;1cm in diameter, individual diameter &lt;7cm and less than 10cm in total diameter.&#xD;
&#xD;
          6. no previous chemotherapy, radiotherapy or transarterial embolization (with or without&#xD;
             chemotherapy) for HCC&#xD;
&#xD;
          7. Preserved liver function (Child-Pugh A or B7).&#xD;
&#xD;
          8. ECOG Performance Status 0 or 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of vascular invasion or extra-hepatic spread of disease, or diffuse HCC,&#xD;
             defined as &gt;50% liver involvement , or arteriovenuous fistula&#xD;
&#xD;
          2. Macrovascular invasion of main or primary branches of portal vein at entry into the&#xD;
             study&#xD;
&#xD;
          3. Any contraindication for TACE treatment&#xD;
&#xD;
          4. Any contraindication for Epirubicin administration&#xD;
&#xD;
          5. Advanced liver disease (bilirubin levels &gt;2 mg/dl, AST or ALT &gt;5 times upper limit of&#xD;
             normal)&#xD;
&#xD;
          6. Renal failure or insufficient renal function (Creatinine levels &gt;2 mg/dl)&#xD;
&#xD;
          7. Subject unable to receive MRI examination&#xD;
&#xD;
          8. Pregnant or breast feeding woman, or plan to become pregnant during treatment or&#xD;
             within 12 months of treatment&#xD;
&#xD;
          9. couldn't commit reliable birth control measures during treatment or within 12 months&#xD;
             of treatment&#xD;
&#xD;
         10. Subject is participating other investigational drug or device clinical trial within 30&#xD;
             days of signing the informed consent&#xD;
&#xD;
         11. Subject is not suitable to participate in the study as judged by investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cathy Peng</last_name>
    <role>Study Director</role>
    <affiliation>BSC China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Affiliated Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital Affiliated China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Aff. Hosp. of Zhejiang University College of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <results_first_submitted>January 15, 2021</results_first_submitted>
  <results_first_submitted_qc>April 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2021</results_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03113955/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03113955/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single -Arm</title>
          <description>A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma&#xD;
Tandem Microsphere loaded with Epirubicin: The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single -Arm</title>
          <description>A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma&#xD;
Tandem Microsphere loaded with Epirubicin: The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Measure Analysis Population Description: A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</population>
          <units>years</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.22" spread="8.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Han of Chinese</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>Measure Analysis Population Description: A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Child-Pugh Score</title>
          <description>Child-Pugh, classification standard is a commonly used clinically to quantitative assessment of the liver reserve function classification standard. when the Child will be five patient's indicators (including the general situation, ascites, the concentration of serum bilirubin, serum albumin, and prothrombin time) of the different states are divided into three levels, 1 point, 2 and 3 points. Five indicators score together, combined the lowest is 5 points, the highest is 15 points, Class A=5 points, Class B=7-9, Class C=10-15, the higher score, the worse the liver reserve function.</description>
          <population>A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Class A</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class B</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease History</title>
          <population>Measure Analysis Population Description: A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Diabetes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cirrhosis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status</title>
          <description>ECOG Performance:&#xD;
0 point is fully active, able to carry on all pre-disease performance without restriction; 1 point is restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; 2 points is ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 points is Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4 points is completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5 points is dead.</description>
          <population>Measure Analysis Population Description: A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0 Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Objective Tumor Response at 6 Months by MRI (Magnetic Resonance Imaging)</title>
        <description>The objective response rate measured by MRI used EASL (European Society for the Study of the Liver) and mRECIST (Improved criteria for evaluating the efficacy of solid tumors) , Overall Response (OR) = CR + PR.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (mRECIST ) for target lesions : Complete Response (CR), Disappearance of any intratumoral arterial enhancement in all target lesions; Partial Response (PR), At least a 30% decrease in the sum of the diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (EASL) for target lesions: Complete Response (CR), Disappearance of all known disease and no new lesions determined by two observations not less than 4 weeks apart; Partial Response (PR), At least 50% reduction in total tumor load of all measurable lesions determined by two observations not less than 4 weeks apart.</description>
        <time_frame>At 6 months</time_frame>
        <population>Total enrolled 109 subjects , 7 subjects were not completed 6 months primary endpoint follow up visit and were not included in the per protocol group for analysis. So overall Number of Participants Analyzed were 102.</population>
        <group_list>
          <group group_id="O1">
            <title>Single -Arm</title>
            <description>A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma&#xD;
Tandem Microsphere loaded with Epirubicin: The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Objective Tumor Response at 6 Months by MRI (Magnetic Resonance Imaging)</title>
          <description>The objective response rate measured by MRI used EASL (European Society for the Study of the Liver) and mRECIST (Improved criteria for evaluating the efficacy of solid tumors) , Overall Response (OR) = CR + PR.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (mRECIST ) for target lesions : Complete Response (CR), Disappearance of any intratumoral arterial enhancement in all target lesions; Partial Response (PR), At least a 30% decrease in the sum of the diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (EASL) for target lesions: Complete Response (CR), Disappearance of all known disease and no new lesions determined by two observations not less than 4 weeks apart; Partial Response (PR), At least 50% reduction in total tumor load of all measurable lesions determined by two observations not less than 4 weeks apart.</description>
          <population>Total enrolled 109 subjects , 7 subjects were not completed 6 months primary endpoint follow up visit and were not included in the per protocol group for analysis. So overall Number of Participants Analyzed were 102.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6-month ORR (EASL criteria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-month ORR (mRECIST criteria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Analyses the Percent of Participants for Time to Progression (TTP) at 12 Months</title>
        <description>Kaplan-Meier analyses the percent of participants for TTP which is defined as the length of time from the treatment initiation to either the date of the first disease progression occurred, as assessed by the investigators, or the date of the subject died due to any cause, whichever comes earlier. EASL and mRECIST response assessment of target lesion for HCC. TTP (also referred as &quot;time to treatment failure&quot;) will be measured by a few data items list below:&#xD;
The date of the disease progression in the Overall Response form&#xD;
The date of lost-to-follow due to:&#xD;
Adverse events&#xD;
Progressive disease/insufficient therapeutic response&#xD;
Death&#xD;
Failure to return&#xD;
Refusing treatment/being unwilling to cooperate/withdrawing consent&#xD;
The very last date by scanning all available dates in the database&#xD;
The desired cut-off days</description>
        <time_frame>At 12 months</time_frame>
        <population>Measure Analysis Population Description: Measure Analysis Population Description: A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Single -Arm</title>
            <description>A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma&#xD;
Tandem Microsphere loaded with Epirubicin: The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Analyses the Percent of Participants for Time to Progression (TTP) at 12 Months</title>
          <description>Kaplan-Meier analyses the percent of participants for TTP which is defined as the length of time from the treatment initiation to either the date of the first disease progression occurred, as assessed by the investigators, or the date of the subject died due to any cause, whichever comes earlier. EASL and mRECIST response assessment of target lesion for HCC. TTP (also referred as &quot;time to treatment failure&quot;) will be measured by a few data items list below:&#xD;
The date of the disease progression in the Overall Response form&#xD;
The date of lost-to-follow due to:&#xD;
Adverse events&#xD;
Progressive disease/insufficient therapeutic response&#xD;
Death&#xD;
Failure to return&#xD;
Refusing treatment/being unwilling to cooperate/withdrawing consent&#xD;
The very last date by scanning all available dates in the database&#xD;
The desired cut-off days</description>
          <population>Measure Analysis Population Description: Measure Analysis Population Description: A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EASL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mRECIST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Objective Tumor Response at 30-day</title>
        <description>The objective response rate measured by MRI used EASL (European Society for the Study of the Liver) and mRECIST (Improved criteria for evaluating the efficacy of solid tumors) , Overall Response (OR) = CR + PR.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (mRECIST ) for target lesions : Complete Response (CR), Disappearance of any intratumoral arterial enhancement in all target lesions; Partial Response (PR), At least a 30% decrease in the sum of the diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (EASL) for target lesions: Complete Response (CR), Disappearance of all known disease and no new lesions determined by two observations not less than 4 weeks apart; Partial Response (PR), At least 50% reduction in total tumor load of all measurable lesions determined by two observations not less than 4 weeks apart.</description>
        <time_frame>At 1month</time_frame>
        <population>Measure Analysis Population Description: Measure Analysis Population Description: A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Single -Arm</title>
            <description>A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma&#xD;
Tandem Microsphere loaded with Epirubicin: The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Objective Tumor Response at 30-day</title>
          <description>The objective response rate measured by MRI used EASL (European Society for the Study of the Liver) and mRECIST (Improved criteria for evaluating the efficacy of solid tumors) , Overall Response (OR) = CR + PR.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (mRECIST ) for target lesions : Complete Response (CR), Disappearance of any intratumoral arterial enhancement in all target lesions; Partial Response (PR), At least a 30% decrease in the sum of the diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (EASL) for target lesions: Complete Response (CR), Disappearance of all known disease and no new lesions determined by two observations not less than 4 weeks apart; Partial Response (PR), At least 50% reduction in total tumor load of all measurable lesions determined by two observations not less than 4 weeks apart.</description>
          <population>Measure Analysis Population Description: Measure Analysis Population Description: A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EASL Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mRECIST Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Analyses the Percent of Participants for PPF(Proportion Progression-Free) at 12 Months</title>
        <description>Kaplan-Meier analyses the percent of participants for PPF which is defined as the length of time from the treatment initiation, that treated subjects are still progression-free. EASL and mRECIST response assessment of target lesion for HCC.&#xD;
The data items to be captured will include:&#xD;
The date of the disease progression in the Overall Response form&#xD;
The very last date by scanning all available dates in the database&#xD;
The desired cut-off days The proportion of any time point will be determined by the Kaplan-Meier estimates.</description>
        <time_frame>from first TACE to 12 months</time_frame>
        <population>Measure Analysis Population Description: Measure Analysis Population Description: A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Single -Arm</title>
            <description>A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma&#xD;
Tandem Microsphere loaded with Epirubicin: The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Analyses the Percent of Participants for PPF(Proportion Progression-Free) at 12 Months</title>
          <description>Kaplan-Meier analyses the percent of participants for PPF which is defined as the length of time from the treatment initiation, that treated subjects are still progression-free. EASL and mRECIST response assessment of target lesion for HCC.&#xD;
The data items to be captured will include:&#xD;
The date of the disease progression in the Overall Response form&#xD;
The very last date by scanning all available dates in the database&#xD;
The desired cut-off days The proportion of any time point will be determined by the Kaplan-Meier estimates.</description>
          <population>Measure Analysis Population Description: Measure Analysis Population Description: A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EASL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mRECIST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Analyses the Percent of Participants for Overall Survival</title>
        <description>Kaplan-Meier analyses the percent of participants for Overall survival which is defined as the length of time from the treatment initiation, that treated subjects are still alive. The Kaplan-Meier analysis is aimed to capture the all-cause death for each subject. Subjects who are lost-to-follow will be considered being censored.&#xD;
There are three critical data items to be captured:&#xD;
Death date&#xD;
The very last date in the database (e.g. follow-up visit date and/or site reported AE date)&#xD;
The desired cut-off days (e.g. 6-month OS at 182 days, 12-month OS at 365 days) In addition to the Kaplan-Meier survival curve, the median survival time (mOS) will also be used to represent the study cohort.</description>
        <time_frame>from first TACE to 12 months</time_frame>
        <population>Measure Analysis Population Description: Measure Analysis Population Description: A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment, 1 subject withdrew consent from study participation at 6 month, 1 subject withdrew consent from study participation at 12 month. All 3 subjects are not included in the group for overall survival analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Single -Arm</title>
            <description>A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma&#xD;
Tandem Microsphere loaded with Epirubicin: The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Analyses the Percent of Participants for Overall Survival</title>
          <description>Kaplan-Meier analyses the percent of participants for Overall survival which is defined as the length of time from the treatment initiation, that treated subjects are still alive. The Kaplan-Meier analysis is aimed to capture the all-cause death for each subject. Subjects who are lost-to-follow will be considered being censored.&#xD;
There are three critical data items to be captured:&#xD;
Death date&#xD;
The very last date in the database (e.g. follow-up visit date and/or site reported AE date)&#xD;
The desired cut-off days (e.g. 6-month OS at 182 days, 12-month OS at 365 days) In addition to the Kaplan-Meier survival curve, the median survival time (mOS) will also be used to represent the study cohort.</description>
          <population>Measure Analysis Population Description: Measure Analysis Population Description: A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment, 1 subject withdrew consent from study participation at 6 month, 1 subject withdrew consent from study participation at 12 month. All 3 subjects are not included in the group for overall survival analysis.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events Relate to Study Device in 12 Months Post Procedure</title>
        <description>Number and documents of adverse events relate to study device in 12 months post procedure</description>
        <time_frame>in 12 months</time_frame>
        <population>Measure Analysis Population Description: Measure Analysis Population Description: A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Single -Arm</title>
            <description>A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma&#xD;
Tandem Microsphere loaded with Epirubicin: The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events Relate to Study Device in 12 Months Post Procedure</title>
          <description>Number and documents of adverse events relate to study device in 12 months post procedure</description>
          <population>Measure Analysis Population Description: Measure Analysis Population Description: A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs of related with TANDEM Microspheres</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-serious AEs of related with TANDEM Microspheresrate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Objective Tumor Response at 3 Months</title>
        <description>The objective response rate measured by MRI used EASL (European Society for the Study of the Liver) and mRECIST (Improved criteria for evaluating the efficacy of solid tumors) , Overall Response (OR) = CR + PR.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (mRECIST ) for target lesions : Complete Response (CR), Disappearance of any intratumoral arterial enhancement in all target lesions; Partial Response (PR), At least a 30% decrease in the sum of the diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (EASL) for target lesions: Complete Response (CR), Disappearance of all known disease and no new lesions determined by two observations not less than 4 weeks apart; Partial Response (PR), At least 50% reduction in total tumor load of all measurable lesions determined by two observations not less than 4 weeks apart.</description>
        <time_frame>At 3 months</time_frame>
        <population>Total enrolled 109 subjects , 4 subjects were not completed 3 months primary endpoint follow up visit and were not included in the per protocol group for analysis. So overall Number of Participants Analyzed were 105.</population>
        <group_list>
          <group group_id="O1">
            <title>Single -Arm</title>
            <description>A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma&#xD;
Tandem Microsphere loaded with Epirubicin: The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Objective Tumor Response at 3 Months</title>
          <description>The objective response rate measured by MRI used EASL (European Society for the Study of the Liver) and mRECIST (Improved criteria for evaluating the efficacy of solid tumors) , Overall Response (OR) = CR + PR.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (mRECIST ) for target lesions : Complete Response (CR), Disappearance of any intratumoral arterial enhancement in all target lesions; Partial Response (PR), At least a 30% decrease in the sum of the diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions.&#xD;
Per Response Evaluation Criteria In Solid Tumors Criteria (EASL) for target lesions: Complete Response (CR), Disappearance of all known disease and no new lesions determined by two observations not less than 4 weeks apart; Partial Response (PR), At least 50% reduction in total tumor load of all measurable lesions determined by two observations not less than 4 weeks apart.</description>
          <population>Total enrolled 109 subjects , 4 subjects were not completed 3 months primary endpoint follow up visit and were not included in the per protocol group for analysis. So overall Number of Participants Analyzed were 105.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EASL Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mRECIST Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Analyses the Percent of Participants for Time to Extrahepatic Spread</title>
        <description>Kaplan-Meier analyses the percent of participants for Time to Extrahepatic Spread which the length of time from the treatment initiation to the development of extrahepatic spread of the disease via imaging assessment.&#xD;
The data items to be considered will include:&#xD;
The date of the extrahepatic spread in the Overall Response form&#xD;
The very last date by scanning all available dates in the database&#xD;
The desired cut-off days</description>
        <time_frame>At 12 month</time_frame>
        <population>Measure Analysis Population Description: Measure Analysis Population Description: A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Single -Arm</title>
            <description>A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma&#xD;
Tandem Microsphere loaded with Epirubicin: The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Analyses the Percent of Participants for Time to Extrahepatic Spread</title>
          <description>Kaplan-Meier analyses the percent of participants for Time to Extrahepatic Spread which the length of time from the treatment initiation to the development of extrahepatic spread of the disease via imaging assessment.&#xD;
The data items to be considered will include:&#xD;
The date of the extrahepatic spread in the Overall Response form&#xD;
The very last date by scanning all available dates in the database&#xD;
The desired cut-off days</description>
          <population>Measure Analysis Population Description: Measure Analysis Population Description: A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>Measure Analysis Population Description: Measure Analysis Population Description: A total of 109 subjects were enrolled, among them one subject coded as 3733S010 was confirmed as cholangiocarcinoma after being enrolled and receiving initial treatment. The subject continuously received follow-up but was not included in the per protocol group for analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Single -Arm</title>
          <description>A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma&#xD;
Tandem Microsphere loaded with Epirubicin: The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver abscess</sub_title>
                <description>There was 6 cases of hepatic abscess reported in the per protocol group</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Jaundice hepatocellular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post embolisation syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Hepatic cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="81" subjects_affected="23" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="48" subjects_affected="27" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="91" subjects_affected="60" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gaojun Teng</name_or_title>
      <organization>Zhongda Hospital Southeast University</organization>
      <phone>13805171500 ext +86</phone>
      <email>gjteng@vip.sina.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

